317 related articles for article (PubMed ID: 20631380)
21. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis.
Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A
FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802
[TBL] [Abstract][Full Text] [Related]
23. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of Mcl-1 exacerbates lymphocyte accumulation and autoimmune kidney disease in lpr mice.
Anstee NS; Vandenberg CJ; Campbell KJ; Hughes PD; O'Reilly LA; Cory S
Cell Death Differ; 2017 Mar; 24(3):397-408. PubMed ID: 27813531
[TBL] [Abstract][Full Text] [Related]
25. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions.
Zhou P; Qian L; Kozopas KM; Craig RW
Blood; 1997 Jan; 89(2):630-43. PubMed ID: 9002967
[TBL] [Abstract][Full Text] [Related]
26. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Yecies D; Carlson NE; Deng J; Letai A
Blood; 2010 Apr; 115(16):3304-13. PubMed ID: 20197552
[TBL] [Abstract][Full Text] [Related]
27. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
28. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
29. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
30. BCL2A1a over-expression in murine hematopoietic stem and progenitor cells decreases apoptosis and results in hematopoietic transformation.
Métais JY; Winkler T; Geyer JT; Calado RT; Aplan PD; Eckhaus MA; Dunbar CE
PLoS One; 2012; 7(10):e48267. PubMed ID: 23118966
[TBL] [Abstract][Full Text] [Related]
31. IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells.
Shenoy AR; Kirschnek S; Häcker G
Eur J Immunol; 2014 Aug; 44(8):2500-7. PubMed ID: 24825007
[TBL] [Abstract][Full Text] [Related]
32. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
Eischen CM; Woo D; Roussel MF; Cleveland JL
Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
[TBL] [Abstract][Full Text] [Related]
34. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival.
Ogilvy S; Metcalf D; Print CG; Bath ML; Harris AW; Adams JM
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14943-8. PubMed ID: 10611317
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.
Högstrand K; Hejll E; Sander B; Rozell B; Larsson LG; Grandien A
PLoS One; 2012; 7(2):e31366. PubMed ID: 22393362
[TBL] [Abstract][Full Text] [Related]
36. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
37. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis in the absence of IL-7.
Huntington ND; Labi V; Cumano A; Vieira P; Strasser A; Villunger A; Di Santo JP; Alves NL
Int Immunol; 2009 Jun; 21(6):715-25. PubMed ID: 19454543
[TBL] [Abstract][Full Text] [Related]
38. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
39. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
40. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
